Published in Vaccine Weekly, December 25th, 2002
"Viral DNA vaccines encoding the glycoprotein B (gB) of cytomegalovirus provide partial protective immunity upon challenge with infectious virus. Although it is known that type 1 IFN can stimulate the adaptive immune response, their direct use in vaccines has been limited," said V.S. Cull and colleagues, Murdoch University, Perth.
They reported that in their study, "in vivo expression of IFN transgenes ranged from 1.2 to 2.0 x 104, IU/g tibialis anterior muscle. Viral...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.